SCHEMBL4254904

SCHEMBL4254904

Cc1cc(-c2nc(-c3ccccc3)co2)ccc1NC(=O)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
SMO Q99835 2/20 0.50
ENPP3 O14638 2/20 0.50
ENPP1 P22413 2/20 0.50
POLB P06746 1/20 0.48
HPGD P15428 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
TP53 P04637 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
ALDH1A1 P00352 2/20 0.47
ADORA1 P30542 2/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4260923 0.86 SMO (0.71) MAPTCYP1A2CYP2C19SMOHPGD
SCHEMBL4263844 0.83 SMO (0.59) MAPTSMOENPP3ENPP1SMN1; SMN2
SCHEMBL14327996 0.77 ENPP3 (0.66) MAPTSMOENPP3ENPP1POLB
SCHEMBL12170985 0.75 HSD17B1 (0.57) SMOENPP3ENPP1NPC1RAB9A
SCHEMBL4262816 0.75 NPC1 (0.62) MAPTSMOPOLBRXFP1ALDH1A1
SCHEMBL17612316 0.74 HSD17B1 (0.53) MAPTSMOENPP3ENPP1POLB
SCHEMBL4254599 0.74 SMO (0.64) MAPTSMOHPGDSMN1; SMN2ALDH1A1
SCHEMBL7881117 0.73 DEGS1 (0.63) MAPTCYP1A2CYP2C9CYP2C19POLB
SCHEMBL18716589 0.73 NR1H4 (0.51) SMOENPP3ENPP1NPC1RAB9A
SCHEMBL30739671 0.72 MAPT (0.69) MAPTCYP1A2CYP2C9CYP2C19POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404722-B2 Oxazole compounds compositions and methods of use AMGEN INC. (US) 2013-03-26 US claimed
US-20110060011-A1 OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2011-03-10 US claimed
WO-2009151495-A2 OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2009-12-17 WO claimed
US-8404722-B2 Oxazole compounds compositions and methods of use AMGEN INC. (US) 2013-03-26 US disclosed
US-20110060011-A1 OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2011-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110060011-A1 OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE OXA1L, CYP11B2, CYP3A7 MAPT 2622/4885CYP1A2 16/4885CYP2C9 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.